These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1099 related articles for article (PubMed ID: 15642275)

  • 21. Efficacy and safety of infliximab in active SLE: a pilot study.
    Uppal SS; Hayat SJ; Raghupathy R
    Lupus; 2009 Jul; 18(8):690-7. PubMed ID: 19502264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus.
    Lub-de Hooge MN; de Vries EG; de Jong S; Bijl M
    Ann Rheum Dis; 2005 Jun; 64(6):854-8. PubMed ID: 15564310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating TNFRI and TNFRII levels correlated with the disease activity score (DAS28) in rheumatoid arthritis.
    Valle Y; Ledezma-Lozano IY; Torres-Carrillo N; Padilla-Gutiérrez JR; Navarro-Hernández RE; Vázquez-Del Mercado M; Palafox-Sánchez CA; Armendáriz-Borunda J; Muñoz-Valle JF
    Scand J Rheumatol; 2009; 38(5):332-5. PubMed ID: 19579138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevation of human tumor necrosis factor-like weak inducer of apoptosis in peripheral blood mononuclear cells is correlated with disease activity and lupus nephritis in patients with systemic lupus erythematosus.
    Liu ZC; Zhou QL; Li XZ; Yang JH; Ao X; Veeraragoo P; Zuo XX
    Cytokine; 2011 Mar; 53(3):295-300. PubMed ID: 21163672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum soluble interleukin-2 receptor alpha in systemic lupus erythematosus.
    El-Shafey EM; El-Nagar GF; El-Bendary AS; Sabry AA; Selim AG
    Iran J Kidney Dis; 2008 Apr; 2(2):80-5. PubMed ID: 19377213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis.
    Robak T; Gladalska A; Stepień H
    Eur Cytokine Netw; 1998 Jun; 9(2):145-54. PubMed ID: 9681390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations.
    Magalhães MB; da Silva LM; Voltarelli JC; Donadi EA; Louzada-Junior P
    Scand J Rheumatol; 2007; 36(6):442-7. PubMed ID: 18092265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum leptin levels in women with systemic lupus erythematosus.
    Garcia-Gonzalez A; Gonzalez-Lopez L; Valera-Gonzalez IC; Cardona-Muñoz EG; Salazar-Paramo M; González-Ortiz M; Martínez-Abundis E; Gamez-Nava JI
    Rheumatol Int; 2002 Aug; 22(4):138-41. PubMed ID: 12172951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese.
    Hao JH; Ye DQ; Zhang GQ; Liu HH; Dai H; Huang F; Pan FM; Su H; Dong MX; Chen H; Wang Q; Zhang XJ
    Arch Dermatol Res; 2006 Jan; 297(7):329-32. PubMed ID: 16328345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Raised serum level of APRIL in patients with systemic lupus erythematosus: correlations with disease activity indices.
    Hegazy M; Darwish H; Darweesh H; El-Shehaby A; Emad Y
    Clin Immunol; 2010 Apr; 135(1):118-24. PubMed ID: 20116334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. VH4-34 encoded antibodies in systemic lupus erythematosus: a specific diagnostic marker that correlates with clinical disease characteristics.
    van Vollenhoven RF; Bieber MM; Powell MJ; Gupta PK; Bhat NM; Richards KL; Albano SA; Teng NN
    J Rheumatol; 1999 Aug; 26(8):1727-33. PubMed ID: 10451069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum albumin as a marker for disease activity in patients with systemic lupus erythematosus.
    Yip J; Aghdassi E; Su J; Lou W; Reich H; Bargman J; Scholey J; Gladman DD; Urowitz MB; Fortin PR
    J Rheumatol; 2010 Aug; 37(8):1667-72. PubMed ID: 20516026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adrenomedullin--a potential disease activity marker and suppressor of nephritis activity in systemic lupus erythematosus.
    Mak A; Cheung BM; Mok CC; Leung R; Lau CS
    Rheumatology (Oxford); 2006 Oct; 45(10):1266-72. PubMed ID: 16595522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel mutation (T61I) in the gene encoding tumour necrosis factor receptor superfamily 1A (TNFRSF1A) in a Japanese patient with tumour necrosis factor receptor-associated periodic syndrome (TRAPS) associated with systemic lupus erythematosus.
    Ida H; Kawasaki E; Miyashita T; Tanaka F; Kamachi M; Izumi Y; Huang M; Tamai M; Origuchi T; Kawakami A; Migita K; Motomura M; Yoshimura T; Eguchi K
    Rheumatology (Oxford); 2004 Oct; 43(10):1292-9. PubMed ID: 15280569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement.
    Oelzner P; Deliyska B; Fünfstück R; Hein G; Herrmann D; Stein G
    Clin Rheumatol; 2003 Oct; 22(4-5):271-8. PubMed ID: 14576989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum free light chains as biomarkers for systemic lupus erythematosus disease activity.
    Aggarwal R; Sequeira W; Kokebie R; Mikolaitis RA; Fogg L; Finnegan A; Plaas A; Block JA; Jolly M
    Arthritis Care Res (Hoboken); 2011 Jun; 63(6):891-8. PubMed ID: 21312346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus.
    Toubi E; Kessel A; Rosner I; Rozenbaum M; Paran D; Shoenfeld Y
    Scand J Immunol; 2006 Apr; 63(4):299-303. PubMed ID: 16623930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytokine imbalance in systemic lupus erythematosus: a study on northern Indian subjects.
    Arora V; Verma J; Marwah V; Kumar A; Anand D; Das N
    Lupus; 2012 May; 21(6):596-603. PubMed ID: 22300832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble adhesion molecules in pediatric rheumatic diseases.
    Bloom BJ; Miller LC; Blier PR
    J Rheumatol; 2002 Apr; 29(4):832-6. PubMed ID: 11950029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics.
    Omdal R; Mellgren SI; Koldingsnes W; Jacobsen EA; Husby G
    J Rheumatol; 2002 Mar; 29(3):482-6. PubMed ID: 11908560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.